Novartis has announced updated analysis from its Phase III NATALEE trial showing that Kisqali (ribociclib) continues to demonstrate sustained reduction in distant recurrence when combined with endocrine therapy. The treatment showed a 28.5% reduction in distant recurrence compared to endocrine therapy alone in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer. “In day-to-day…
Merck has announced that its Phase 3 KEYLYNK-001 trial met its primary endpoint of progression-free survival (PFS) in patients with advanced epithelial ovarian cancer. The study evaluated KEYTRUDA plus chemotherapy followed by maintenance with LYNPARZA, with or without bevacizumab, as a first-line treatment for people with BRCA non-mutated advanced epithelial ovarian cancer. “For people living with ovarian cancer, there remains an unmet…
Gabbi, a women’s virtual breast health platform, has announced a partnership with ByteDance to provide breast cancer risk assessment and specialist access to the tech company’s global workforce. The initiative launches for over 16,000 individuals in the United States, with planned expansion to Canada this month, followed by Australia, France, and the United Kingdom in March 2025. The collaboration challenges traditional breast…
AbbVie has received European Commission (EC) marketing authorization for ELAHERE (mirvetuximab soravtansine) for the treatment of platinum-resistant ovarian cancer. The approval marks the first folate receptor alpha (FRɑ)-directed antibody drug conjugate approved in the European Union, Iceland, Liechtenstein, Norway, and Northern Ireland. The treatment specifically targets adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or…
DeepHealth has announced its acquisition of UK-based Kheiron Medical Technologies, marking a significant consolidation in the AI-powered breast cancer screening space. The acquisition brings together DeepHealth’s Smart Mammo platform with Kheiron’s Mia (Mammography Intelligent Assessment) suite of solutions. The move appears strategically timed as AI continues to gain traction in medical imaging, particularly in mammography where radiologist shortages and increasing screening volumes…
Teal Health, a woman-led company focused on cervical cancer screening, has been awarded a $1.68 million Small Business Innovation Research (SBIR) Direct to Phase II Grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The grant will support the development and clinical validation of the Teal Wand, a device designed for at-home collection of vaginal samples for…
The U.S. Food and Drug Administration (FDA) has approved Genentech’s Itovebi (inavolisib) for the treatment of advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a PIK3CA mutation. Itovebi is to be used in combination with palbociclib (Ibrance) and fulvestrant. This approval is based on results from the Phase III INAVO120 study, which showed that the Itovebi-based…
Midi Health, a virtual care clinic for women 35 and older, has announced the launch of a Survivorship Program. This program aims to provide menopause care for breast cancer survivors and women at high risk for breast cancer. The program was developed and is led by Dr. Mindy Goldman, a Clinical Professor in the Department of OB/GYN at UC San Francisco and…
